BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31594236)

  • 1. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
    Baig AM
    ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
    Cho JE; Kim JR
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
    Malafaia D; Albuquerque HMT; Silva AMS
    Eur J Med Chem; 2021 Mar; 214():113209. PubMed ID: 33548635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs for Targeted Therapies of Alzheimer's Disease.
    Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
    Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the development of new drugs in Alzheimer's disease.
    Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
    J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.